Share

August 2015; 2 (4) ArticleOpen Access

Caspr2 autoantibodies target multiple epitopes

Abby L. Olsen, Yongjie Lai, Josep Dalmau, Steven S. Scherer, Eric Lancaster
First published July 2, 2015, DOI: https://doi.org/10.1212/NXI.0000000000000127
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1247

Share

Article Information

vol. 2 no. 4 e127
DOI: 
https://doi.org/10.1212/NXI.0000000000000127
PubMed: 
26185774
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received October 7, 2014
  • Accepted in final form May 22, 2015
  • First Published July 2, 2015.
Copyright & Usage: 
© 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Abby L. Olsen, MD, PhD,
    2. Yongjie Lai, MD,
    3. Josep Dalmau, MD, PhD,
    4. Steven S. Scherer, MD, PhD and
    5. Eric Lancaster, MD, PhD
  1. Abby L. Olsen, MD, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Yongjie Lai, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Josep Dalmau, MD, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Neurology, Neuroimmunology and Neuroinflammation Neurology UpToDate

    Patents:

    1. Patent for Ma2 autoantibody test, patent number: 6,387,639; Issued May 14th, 2002 Patent for NMDA receptor autoantibody test; US 7,972,796 B2 July 5, 2011; European 2057466 Patents filed for GABA(B) receptor autoantibody test, GABA(A) receptor autoantibody test, DPPX autoantibody test, and IgLON5 autoantibody test.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Advance Medical

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Euroimmun, research support

    Research Support, Government Entities:

    1. -NIH, RO1NS077851 (previously RO1CA107192), PI, 2011-2016 -NIMH, Eureka 1RO1MH094741, Co-PI, 2011-2015 -Instituto Carlos III, (FIS, 14/00203)-Ag?ncia de Gesti? d?Ajuts Universitaris i de Recerca (AGAUR, Generalitat de Catalunya

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NMDA receptor autoantibody test/Euroimmun GABA(B)R autoantibody test/Euroimmun GABA(A)R autoantibody test/Euroimmun DPPX autoantibody test/Euroimmun Iglon5 autoantibody test/Euroimmun

    Royalty Payments, Technology or Inventions:

    1. Patent Ma2 autoantibody test Patent NMDAR autoantibody test Patent application for the use of GABA(B) receptor, GABA (A) receptor, DPPX and IgLON5 autoantiboddy tests

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Steven S. Scherer, MD, PhD and
    5. Scientific Advisory Boards:

    1. I am on the SAB for the Charcot-Marie-Tooth Association. I receive no financial compensation for this.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Cell and Tissue Research 2001-present; no compensation Experimental Neurology 2007-present; no compensation Glia 2011-present Journal of Neuroscience Research 2002-present; no compensation Journal of the Peripheral Nervous System 2007-present; no compensation

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Commercial or non-profit entity Lundbeck: phone call interview, March 2011 Scisive: phone call interview, July 2011 Clarion Consulting: phone call interview, April 2012 Pfizer: moderated a session, ?TTR-amyloidosis ? from gene discovery to treatment?, at the Peripheral Nerve Society Meeting in St. Malo, France, June 30, 2013. Guidepoint Global Advisors: phone call interview, November 2013 Cydan: phone call interview, November 2013 Grifols: helped prepare and gave a Power Point presentation on CIDP to sales reps, and participated in day-long didactic sessions, September 15-16, 2014

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. RO1 NS079683 (co-PI) 7/1/013-6/30/18 ?Autoimmune mechanisms in a novel Aire-deficient model of peripheral neuropathy? NIH/NINDS RO1 NS42878 (PI) 9/1/11 ? 8/30/16 ?The Role of Connexin32 in the Pathogenesis of CMTX? U54 NS065712 (PI) 10/1/09 - 9/30/14 ?Inherited Neuropathies - an integrative approach leading to therapy?

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Muscular Dystrophy Association (Co-PI) 2/1/12-1/31/15 ?Mechanisms of CNS Disease in CMT1X? National Multiple Sclerosis Society (PI) 4/1/11 ? 3/31/14 ?Essential Roles of Gap Junction Proteins in Oligodendrocytes?

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Eric Lancaster, MD, PhD
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Grifols Inc. Honoraria for teaching in courses to train their sales team about CIDP.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Medimmune Inc., fees for expert consultation.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. (1) Federal Vaccine Injury Compensation Program. Fees for expert review of cases.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Talecris Inc. provided an educational grant. (2) Lindbeck Inc. funded a grant I received from the National Organization for Rare Disorders.

    Research Support, Government Entities:

    1. (1) NINDS, K08 NS075142, PI, 2013-2017.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) DANA foundation, Neuroimmunology Award, 2010-2015.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (A.L.O., Y.L., J.D., S.S.S., E.L.), The University of Pennsylvania, Philadelphia; and ICREA-IDIBAPS (J.D.), Hospital Unit, University of Barcelona, Spain.
  1. Correspondence to Dr. Lancaster: eric.lancaster{at}uphs.upenn.edu
View Full Text

Article usage

Article usage: July 2015 to August 2023

AbstractFullPdfSource
Jul 20151751624Highwire
Jul 201505130pmc
Aug 20152482132Highwire
Aug 201504322pmc
Sep 2015641315Highwire
Sep 201503217pmc
Oct 201549410Highwire
Oct 20150205pmc
Nov 2015331313Highwire
Nov 201503222pmc
Dec 201529137Highwire
Dec 201502012pmc
Jan 201614954Highwire
Jan 201602521pmc
Feb 201623710Highwire
Feb 201602518pmc
Mar 201626220Highwire
Mar 20160268pmc
Apr 20161927Highwire
Apr 201602612pmc
May 201615106Highwire
May 2016084pmc
Jun 201617717Highwire
Jun 2016099pmc
Jul 201636513Highwire
Jul 20160206pmc
Aug 20161129Highwire
Aug 20160139pmc
Sep 20161513Highwire
Sep 201601811pmc
Oct 201613122Highwire
Oct 20160175pmc
Nov 201629413Highwire
Nov 2016055pmc
Dec 201618311Highwire
Dec 2016041pmc
Jan 20172133Highwire
Jan 20170106pmc
Feb 2017743Highwire
Feb 201701410pmc
Mar 20172976Highwire
Mar 20170102pmc
Apr 20171341Highwire
Apr 20174911pmc
May 2017835Highwire
May 2017376pmc
Jun 20171113Highwire
Jun 2017589pmc
Jul 2017914Highwire
Jul 2017297pmc
Aug 20171023Highwire
Aug 2017276pmc
Sep 2017542Highwire
Sep 20176815pmc
Oct 2017350Highwire
Oct 201751010pmc
Nov 2017833Highwire
Nov 2017178pmc
Dec 2017587Highwire
Jan 20182162Highwire
Feb 20180183Highwire
Mar 20180281Highwire
Apr 20184181Highwire
Apr 201871111pmc
May 20180424Highwire
Jun 20181263Highwire
Jun 201831013pmc
Jul 20181359Highwire
Aug 20181253Highwire
Aug 201831417pmc
Sep 20180294Highwire
Oct 20180203Highwire
Nov 20182373Highwire
Dec 20181415Highwire
Jan 201923410Highwire
Feb 20195263Highwire
Mar 20192444Highwire
Apr 20194216Highwire
May 20194295Highwire
Jun 20193154Highwire
Jul 201975510Highwire
Aug 20192316Highwire
Sep 2019275Highwire
Oct 20194696Highwire
Nov 201934612Highwire
Dec 20194266Highwire
Jan 20201223Highwire
Feb 202022311Highwire
Mar 20200206Highwire
Apr 20202908Highwire
May 20201188Highwire
Jun 202043014Highwire
Jul 202002910Highwire
Aug 20201124Highwire
Sep 202033011Highwire
Oct 202006126Highwire
Nov 202054020Highwire
Dec 20201135Highwire
Jan 202143121Highwire
Feb 202112510Highwire
Mar 20211237Highwire
Apr 20212329Highwire
May 202153412Highwire
Jun 202123015Highwire
Jul 202112633Highwire
Aug 202112112Highwire
Sep 20213269Highwire
Oct 202114622Highwire
Nov 202123820Highwire
Dec 20211508Highwire
Jan 20223234Highwire
Feb 20223238Highwire
Mar 202232812Highwire
Apr 202213214Highwire
May 202282622Highwire
Jun 202222621Highwire
Jul 20220232Highwire
Aug 202264210Highwire
Sep 202233518Highwire
Oct 202234112Highwire
Nov 20222713421Highwire
Dec 202222510Highwire
Jan 20233419Highwire
Feb 202333710Highwire
Mar 20230155Highwire
Apr 202332310Highwire
May 202333313Highwire
Jun 20233145Highwire
Jul 20231209Highwire
Aug 20231216Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me

Recommended articles